CX3CR1, C-X3-C motif chemokine receptor 1, 1524

N. diseases: 310; N. variants: 10
Disease: Hyperalgesia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.210 Biomarker phenotype BEFREE BACKGROUND Fractalkine is widely expressed throughout the brain and spinal cord, where it can exert effects on pain enhancement and hyperalgesia by activating microglia through CX3C chemokine receptor 1 (CX3CR1), which triggers the release of several pro-inflammatory cytokines in the spinal cord. 30517088 2018
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.210 Biomarker phenotype RGD Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. 22647647 2012
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.210 Biomarker phenotype RGD Interleukin-6 induces microglial CX3CR1 expression in the spinal cord after peripheral nerve injury through the activation of p38 MAPK. 19959384 2010
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.210 Biomarker phenotype RGD Intrathecal injection of anti-CX3CR1 neutralizing antibody both delayed the development of ambulatory pain and hyperalgesia and attenuated established pain facilitation, but had no effects on destruction of bone. 20736819 2010
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.210 Biomarker phenotype RGD An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. 16324111 2005